KEYNOTE ADDRESS
Getting to ‘No’: Accelerating Proof of Concept to Speed Development and Manage Risk
Kenneth I. Kaitin, Ph.D., Director, Tufts Center for the Study of Drug Development
|
SESSION TOPICS
- Preclinical & Early Development to Reduce Attrition
- Biomarkers & Pharmacogenomics:
Early Phase Development Acceleration
- Proof-of-Concept: Science to Strategy
- Innovative & Adaptive Clinical Trial Design
- Case Studies
FEATURED SPEAKERS
Walter Janssens, Ph.D., Senior Preclinical Assessor, Preauthorisation, Coordinator Early Phase Development, Federal Agency for Medicines and Health Products
Chris H. Takimoto, M.D., Ph.D., Senior Director, Translational Medicine, Ortho Biotech Oncology R&D/Centocor R&D, Inc.
Coreen Oei, Ph.D., Vice President, Scientific & Clinical Operations, GlaxoSmithKline
Joseph C. Fleishaker, Ph.D., FAAPS, FCP, VP, PGRD, St. Louis Laboratories, Clinical Research, Pfizer Inc.
Thierry Sornasse, Ph.D., Director, Translational Medicine, Biomarker Integration, Elan Pharmaceuticals, Inc.
Martin Wehling, M.D., Managing Director, Institute for Experimental and Clinical Pharmacology and Toxicology,
Director, Clinical Pharmacology Mannheim Medical Faculty, Mannheim Ruprecht-Karls-University Heidelberg
SHORT COURSE
- Evidence Led Decision Making for Clinical Proof-of-Concepts